Premium
Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease
Author(s) -
Kordower Jeffrey H.,
Palfi Stephane,
Chen ErYun,
Ma Shuang Y.,
Sendera Timothy,
Cochran Elizabeth J.,
Mufson Elliott J.,
Penn Richard,
Goetz Christopher G.,
Comella Cynthia D.
Publication year - 1999
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/1531-8249(199909)46:3<419::aid-ana21>3.0.co;2-q
Subject(s) - glial cell line derived neurotrophic factor , medicine , parkinson's disease , parkinsonism , neurotrophic factors , tolerability , anesthesia , disease , neuroscience , psychology , adverse effect , receptor
As part of a safety and tolerability study, a 65‐year‐old man with Parkinson's disease (PD) received monthly intracerebroventricular injections of glial‐derived neurotrophic factor (GDNF). His parkinsonism continued to worsen following intracerebroventricular GDNF treatment. Side effects included nausea, loss of appetite, tingling, L'hermitte's sign, intermittent hallucinations, depression, and inappropriate sexual conduct. There was no evidence of significant regeneration of nigrostriatal neurons or intraparenchymal diffusion of the intracerebroventricular GDNF to relevant brain regions. Alternative GDNF delivery systems should be explored.